Jafron Biomedical Co Ltd
SZSE:300529
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.6
37.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Jafron Biomedical Co Ltd
Income from Continuing Operations
Jafron Biomedical Co Ltd
Income from Continuing Operations Peer Comparison
300760
688271
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
Income from Continuing Operations
¥701.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
A
|
APT Medical Inc
SSE:688617
|
Income from Continuing Operations
¥522.1m
|
CAGR 3-Years
71%
|
CAGR 5-Years
99%
|
CAGR 10-Years
N/A
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Income from Continuing Operations
¥2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
21%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Income from Continuing Operations
¥12.7B
|
CAGR 3-Years
19%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
L
|
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
|
Income from Continuing Operations
¥984.4m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
9%
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Income from Continuing Operations
¥2B
|
CAGR 3-Years
28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Jafron Biomedical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
701.3m
CNY
Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Income from Continuing Operations amounts to 701.3m CNY.
What is Jafron Biomedical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
7%
Over the last year, the Income from Continuing Operations growth was 71%. The average annual Income from Continuing Operations growth rates for Jafron Biomedical Co Ltd have been -13% over the past three years , 7% over the past five years .
You don't have any saved screeners yet
